For research use only. Not for therapeutic Use.
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al[1].
NDMC101 (10-15 µM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells[1]. NDMC101 (15 µM) decreases RANKL-induced expression of the osteoclastogenic genes Nfatc1, Acp5, Ctsk, Oscar, Itgb3, and Dcstamp in BMDMs[1].
| Catalog Number | R066779 |
| CAS Number | 1308631-40-4 |
| Synonyms | N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide |
| Molecular Formula | C13H9ClFNO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H9ClFNO2/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17/h1-7,17H,(H,16,18) |
| InChIKey | NUQWCDAXACRITO-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)C(=O)NC2=C(C=C(C=C2)Cl)F)O |
| Reference | [1]. Chia-Pi Cheng, et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. [2]. Jun-Ting Liou, et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. |
